CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

The FDA approved Agios Pharmaceuticals’ drug mitapivat to treat thalassemia on Tuesday, under the name Aqvesme, following a three-month delay and a missed deadline. The

Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi

Companies that have voluntarily agreed to drug pricing deals with the White House appear to be exempt from two new CMS demonstration programs that have

Plus, news about BioMarin and Cassava. 💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based